Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy
European Journal of Neurology · 2025
DOI: 10.1111/ene.70087 ↗At a glance
Journal article in European Journal of Neurology, 2025. Written by Valentine Perrain and 5 co-authors. Institution: Département de Neurologie, AP-HP, Hôpital Henri Mondor, Créteil, France. Major MEDLINE topics: Immunoglobulin A, Paraproteinemias, Peripheral Nervous System Diseases. 15 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Neuropathies associated with IgA monoclonal gammopathy are poorly understood, and the interpretation of the presence of such gammopathy in a patient with neuropathy may be challenging.
Methods
The neurological and hematological features of all patients newly diagnosed with IgA gammopathy by immunofixation in our center from January 2016 to December 2020 were retrospectively analyzed. Patients with neuropathy were identified through the medical records. The etiology was reviewed by two neurologists and classified into three groups: (i) IgA‐related neuropathies, (ii) IgA‐unrelated neuropathies with an identified alternative etiology, and (iii) neuropathies of uncertain relationship with IgA (NURIA) based on a negative extensive work‐up.
Results
Among 585 patients with IgA gammopathy, 79 had neuropathy (14%). Neuropathy was IgA‐related in 10 patients (13%): eight AL amyloidosis and two POEMS. In this group, the core features were neuropathic pain, autonomic dysfunction, fatigue or weight loss, and a lambda light chain. IgA‐unrelated neuropathies were more frequent ( N = 64, 81%), encompassing mainly chemotherapy‐induced ( N = 34) and diabetic ( N = 15) neuropathies. Five patients (6%) were classified as NURIA: four had mild sensory‐predominant length‐dependent axonal neuropathy, and one had severe, progressive, motor‐predominant axonal neuropathy.
Conclusions
In patients with IgA gammopathy, neuropathies have a low prevalence and a wide etiological spectrum. AL amyloidosis and POEMS syndrome are rare but crucial to identify, as disease‐modifying treatments are available. Future studies should help better characterize the rare cases of neuropathy with an uncertain relationship to IgA gammopathy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Département de Neurologie, AP-HP, Hôpital Henri Mondor, Créteil, France.
- Département d'Hématologie-Immunologie, AP-HP, Hôpital Henri Mondor, Créteil, France.
- Département d'Hématologie, AP-HP, Hôpital Henri Mondor, Créteil, France.
- AP-HP, Reference Center for Neuromuscular Diseases Nord/Est/Ile-de-France, Paris, France.
- Faculty of Health, UR 4391 (ENT Team), Paris Est Creteil University (UPEC), Creteil, France.
- Département de Neurophysiologie Clinique, AP-HP, Hôpital Henri Mondor, Créteil, France.
ORCID profiles: Valentine Perrain, Alain Créange, Thierry Gendre
Cite
APA
Perrain, V., Molinier-Frenkel, V., Dupuis, J., Créange, A., Lefaucheur, J. P., & Gendre, T. (2025). Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy. European Journal of Neurology. https://doi.org/10.1111/ene.70087
Vancouver
Perrain V, Molinier-Frenkel V, Dupuis J, Créange A, Lefaucheur JP, Gendre T. Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy. European Journal of Neurology. 2025. doi:10.1111/ene.70087
BibTeX
@article{Perrain2025,
author = {Perrain, Valentine and Molinier-Frenkel, Valérie and Dupuis, Jehan and Créange, Alain and Lefaucheur, Jean-Pascal and Gendre, Thierry},
title = {Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70087}
}
EUVIMED